Trial Profile
A single-center, open-label study with 14C-labelled ACT-064992 to investigate the mass balance, pharmacokinetics, and metabolism following single oral administration to healthy male subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Aug 2014
Price :
$35
*
At a glance
- Drugs Macitentan (Primary)
- Indications Eisenmenger complex; Glioblastoma; Idiopathic pulmonary fibrosis; Pulmonary arterial hypertension; Skin ulcer
- Focus Pharmacokinetics
- 14 Aug 2014 New trial record